Mixtard 30 Innolet (Insulin Human)

Insulin human, the active ingredient in Mixtard 30 Innolet, is an insulin presented as a prefilled injection pen for subcutaneous use. It treats hyperglycemia in patients with type 1 and type 2 diabetes mellitus by providing both rapid‑acting and intermediate‑acting insulin components.

GNH USA supplies Mixtard 30 Innolet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. Clients benefit from timely delivery and comprehensive regulatory support.

Mixtard 30 Innolet is a premixed insulin used in the management of diabetes mellitus.

Type 1 diabetes mellitus: provides basal and prandial insulin coverage to achieve target blood glucose levels. Type 2 diabetes mellitus: supplements oral agents or diet therapy to improve glycemic control when additional insulin is required. Hospitalized patients with hyperglycemia: enables rapid correction of elevated blood glucose levels during acute care. Patients requiring basal‑bolus regimen simplification: offers combined basal and rapid‑acting insulin in one injection. Insulin therapy in pediatric type 1 diabetes: provides age‑appropriate dosing flexibility for children and adolescents.

Mixtard 30 Innolet may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Hypoglycemia: symptoms such as sweating, tremor, or confusion due to low blood glucose. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with insulin therapy. - Lipodystrophy: localized changes in fat tissue at injection sites.

Serious or Rare Side Effects: - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Severe hypoglycemia leading to loss of consciousness or seizures. - Insulin edema: rapid fluid retention causing swelling.

When using Mixtard 30 Innolet, several precautions should be observed to ensure safe and effective therapy.

Dose adjustment: tailor the insulin dose based on blood glucose monitoring, diet, and activity levels. Renal impairment: monitor closely as reduced clearance may increase hypoglycemia risk. Hepatic dysfunction: use with caution because altered insulin metabolism can affect glucose control. Concomitant medications: review other drugs that may potentiate or diminish insulin effects. Pregnancy and lactation: assess risk–benefit; insulin is the preferred agent but dosing may need modification. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the pen.

Mixtard 30 Innolet can interact with other medicines, influencing its glucose‑lowering action.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycemia symptoms and prolong insulin effect. - MAO‑A inhibitors: can potentiate insulin’s hypoglycemic action. - Corticosteroids: may cause significant hyperglycemia, requiring insulin dose increase.

Moderate Interactions (Monitor Closely): - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides): additive risk of hypoglycemia. - Thiazide diuretics: may raise blood glucose, necessitating dose adjustment. - Alcohol: can cause unpredictable glucose fluctuations and enhance hypoglycemia risk.